Ascletis Pharma Inc. (ASCLETIS-B) filed a Next Day Disclosure Return for 8 June 2026, confirming further progress under its ongoing share-repurchase programme on the Hong Kong Stock Exchange.

Key transaction • On 8 June 2026 the company bought back 200,000 ordinary shares on-market at prices ranging from HK$9.88 to HK$10.26, for a total consideration of HK$2.01 million. The volume-weighted average price was approximately HK$10.04 per share. • The repurchased shares are earmarked for cancellation; none will be held as treasury stock.

Programme status • Since the current mandate was approved on 22 May 2025, Ascletis has repurchased 7.29 million shares, equal to 0.76 % of the 963 million shares outstanding on the mandate date. • The mandate still allows a further 89.00 million shares to be bought back before expiry. • All repurchased shares—now totalling 6.79 million as of 8 June 2026—await formal cancellation.

Share capital position (post-transaction, pre-cancellation) • Issued shares (excluding treasury): 1.06 billion. • Treasury shares on hand: 7.08 million. • Total issued shares (including treasury): 1.07 billion.

Pricing context • The latest purchase price range (HK$9.88–10.26) sits below the weighted-average HK$10.52 paid for the four trading sessions from 2–5 June 2026, indicating disciplined price sensitivity in execution.

Other information • In accordance with HKEX rules, Ascletis is restricted from issuing new shares or selling treasury shares until 8 July 2026, 30 days after the most recent repurchase.

The company affirmed that all buy-backs were conducted in compliance with the Hong Kong Listing Rules and the explanatory statement dated 29 April 2025.